143 related articles for article (PubMed ID: 38741835)
1. Role of Acamprosate and Baclofen as Anti-craving Agents in Alcohol Use Disorder: A 12-Week Prospective Study.
Sharma AK; Rikhari P; Shukla AK; Rikhari P
Cureus; 2024 Apr; 16(4):e58174. PubMed ID: 38741835
[TBL] [Abstract][Full Text] [Related]
2. Baclofen for alcohol use disorder.
Agabio R; Saulle R; Rösner S; Minozzi S
Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012557. PubMed ID: 36637087
[TBL] [Abstract][Full Text] [Related]
3. Baclofen for alcohol use disorder.
Minozzi S; Saulle R; Rösner S
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
[TBL] [Abstract][Full Text] [Related]
4. A comparative study on the safety and efficacy of naltrexone versus baclofen versus acamprosate in the management of alcohol dependence.
Kumar A; Sharma A; Bansal PD; Bahetra M; Gill HK; Kumar R
Indian J Psychiatry; 2020; 62(6):650-658. PubMed ID: 33896969
[TBL] [Abstract][Full Text] [Related]
5. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Namkoong K; Lee BO; Lee PG; Choi MJ; Lee E
Alcohol Alcohol; 2003; 38(2):135-41. PubMed ID: 12634260
[TBL] [Abstract][Full Text] [Related]
6. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol.
Chick J; Howlett H; Morgan MY; Ritson B
Alcohol Alcohol; 2000; 35(2):176-87. PubMed ID: 10787394
[TBL] [Abstract][Full Text] [Related]
7. High craving is associated with fewer abstinent days and lesser time to relapse during treatment in severe alcohol use disorder.
Soundararajan S; Murthy P
Indian J Psychiatry; 2023 Mar; 65(3):319-326. PubMed ID: 37204968
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial.
Hauser P; Fuller B; Ho SB; Thuras P; Kern S; Dieperink E
Addiction; 2017 Jul; 112(7):1173-1183. PubMed ID: 28192622
[TBL] [Abstract][Full Text] [Related]
9. Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
Tyson LD; Cheng A; Kelleher C; Strathie K; Lovendoski J; Habtemariam Z; Lewis H
Eur J Gastroenterol Hepatol; 2022 May; 34(5):567-575. PubMed ID: 35421022
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
[TBL] [Abstract][Full Text] [Related]
11. Randomized open-label trial of baclofen for relapse prevention in alcohol dependence.
Gupta M; Verma P; Rastogi R; Arora S; Elwadhi D
Am J Drug Alcohol Abuse; 2017 May; 43(3):324-331. PubMed ID: 27808555
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
[TBL] [Abstract][Full Text] [Related]
13. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
Soyka M; Preuss U; Schuetz C
Drugs R D; 2002; 3(1):1-12. PubMed ID: 11881521
[TBL] [Abstract][Full Text] [Related]
14. Novel paradigms for the gut-brain axis during alcohol withdrawal, withdrawal-associated depression, and craving in patients with alcohol use disorder.
Vatsalya V; Verster JC; Sagaram M; Royer AJ; Hu H; Parthasarathy R; Schwandt ML; Kong M; Ramchandani VA; Feng W; Agrawal R; Zhang X; McClain CJ
Front Psychiatry; 2023; 14():1203362. PubMed ID: 37840804
[TBL] [Abstract][Full Text] [Related]
15. Relapse prevention for alcohol use disorders: combined acamprosate and cue exposure therapy as aftercare.
Stryhn L; Larsen MB; Mejldal A; Sibbersen C; Nielsen DG; Nielsen B; Nielsen AS; Stenager E; Mellentin AI
Nord J Psychiatry; 2022 Jul; 76(5):394-402. PubMed ID: 34622734
[TBL] [Abstract][Full Text] [Related]
16. Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder.
Ho MF; Zhang C; Moon I; Coombes BJ; Biernacka J; Skime M; Choi DS; Croarkin PE; Frye MA; Ngo Q; Skillon C; Oesterle TS; Karpyak VM; Li H; Weinshilboum RM
Front Pharmacol; 2022; 13():986238. PubMed ID: 36120372
[TBL] [Abstract][Full Text] [Related]
17. Ability of baclofen in reducing alcohol craving and intake: II--Preliminary clinical evidence.
Addolorato G; Caputo F; Capristo E; Colombo G; Gessa GL; Gasbarrini G
Alcohol Clin Exp Res; 2000 Jan; 24(1):67-71. PubMed ID: 10656195
[TBL] [Abstract][Full Text] [Related]
18. Elevated Glutamate Levels in the Left Dorsolateral Prefrontal Cortex Are Associated with Higher Cravings for Alcohol.
Frye MA; Hinton DJ; Karpyak VM; Biernacka JM; Gunderson LJ; Geske J; Feeder SE; Choi DS; Port JD
Alcohol Clin Exp Res; 2016 Aug; 40(8):1609-16. PubMed ID: 27439218
[TBL] [Abstract][Full Text] [Related]
19. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain.
Gual A; Lehert P
Alcohol Alcohol; 2001; 36(5):413-8. PubMed ID: 11524307
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study.
Ho MF; Zhang C; Wei L; Zhang L; Moon I; Geske JR; Skime MK; Choi DS; Biernacka JM; Oesterle TS; Frye MA; Seppala MD; Karpyak VM; Li H; Weinshilboum RM
Br J Pharmacol; 2022 Jul; 179(13):3330-3345. PubMed ID: 35016259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
